NCT06623110: An ongoing trial by Glenn J. Hanna
This trial is ongoing. It must report results 2 years, 4 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06623110 |
|---|---|
| Title | A Phase 2 Study of Intralesional RP2 as Immunoprevention for High-Risk Oral Precancerous Disease (INTERCEPT) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Jan. 1, 2025 |
| Completion date | Jan. 1, 2027 |
| Required reporting date | Jan. 1, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Aug. 26, 2025 |
| Days late | None |